0001567619-20-001197.txt : 20200116 0001567619-20-001197.hdr.sgml : 20200116 20200116200058 ACCESSION NUMBER: 0001567619-20-001197 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200114 FILED AS OF DATE: 20200116 DATE AS OF CHANGE: 20200116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES CENTRAL INDEX KEY: 0001221590 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 20532085 MAIL ADDRESS: STREET 1: 925 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc1.xml FORM 4 X0306 4 2020-01-14 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 1 1 0 0 Chief Executive Officer Common Stock 2020-01-14 4 M 0 8000 21.51 A 335530 D Common Stock 2020-01-14 4 S 0 8000 87.95 D 327530 D Common Stock 180261 I Shares held by Jean-Jacques Bienaime Family Trust Stock Option (Right to buy Common Stock) 21.51 2020-01-14 4 M 0 8000 0 D 2010-11-12 2020-05-11 Common Stock 8000 100000 D Trade made pursuant to a 10b5-1 plan executed on November 13, 2019. The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 10 shares, with the reporting person's purchase of shares at a price of $75.3786 on November 11, 2019. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Eric Fleekop, Attorney-in-Fact 2020-01-16